MEDIA ADVISORY --- BIO CEO & Investor Conference 2002: Highlight of Events for Friday, February 22, 2002
WHERE: Waldorf=Astoria Hotel, New York
10:40 a.m. – 12: 00 p.m.
Investor Session 13
Jade Room
Enhancing the Therapeutic Profile of Anti-cancer Compounds Through Drug Delivery
10:40 a.m. – 12:00 p.m.
Investor Session 14
Astor Room
Street Smarts: Positioning Your Company and Maintaining Credibility in a Tough Market — This panel will discuss creative IR strategies to showcase biotech companies and manage negative perceptions from the Street.
10:40 a.m. – 12:00 p.m.
CEO Roundtable 10
East Foyer
Developments in the World of Big Pharma: The Potential Impacts on the Biotechnology Industry — CEOs will discuss the several policy issues: legislative initiatives and FDA guidelines that may affect the development of generic biologics, FTC investigations into IP and antitrust laws, and government and legal investigations into the drug pricing and marketing practices of pharmaceutical companies.
10:40 a.m. – 12: 00 p.m.
Investor Session 13
Jade Room
Enhancing the Therapeutic Profile of Anti-cancer Compounds Through Drug Delivery
10:40 a.m. – 12:00 p.m.
Investor Session 14
Astor Room
Street Smarts: Positioning Your Company and Maintaining Credibility in a Tough Market — This panel will discuss creative IR strategies to showcase biotech companies and manage negative perceptions from the Street.
10:40 a.m. – 12:00 p.m.
CEO Roundtable 10
East Foyer
Developments in the World of Big Pharma: The Potential Impacts on the Biotechnology Industry — CEOs will discuss the several policy issues: legislative initiatives and FDA guidelines that may affect the development of generic biologics, FTC investigations into IP and antitrust laws, and government and legal investigations into the drug pricing and marketing practices of pharmaceutical companies.
12:00 – 1:30 p.m.
CLOSING PLENARY
Grand Ballroom
Managing Through Biotech’s Binary Events — Top analysts and industry leaders will participate in a roundtable discussion about managing risks, expectations and results of FDA approval decisions.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit www.bio.org.
###